Clinical development of insulin-like growth factor receptor—1 (IGF-1R) inhibitors: At the crossroad? by Andrea Gombos et al.
REVIEW
Clinical development of insulin-like growth factor
receptor—1 (IGF-1R) inhibitors: At the crossroad?
Andrea Gombos & Otto Metzger-Filho &
Lissandra Dal Lago & Ahmad Awada-Hussein
Received: 21 January 2012 /Accepted: 28 February 2012 /Published online: 14 March 2012
# The Author(s) 2012. This article is published with open access at Springerlink.com
Summary Insulin like growth factor receptor (IGF-1R) tar-
geting became one of the most investigated areas in anticancer
drug development during the last decade. Strategies aiming to
block IGF-1R activity include monoclonal antibodies, tyro-
sine kinase inhibitors and anti-ligands antibodies. Initial en-
thusiasm quickly encountered challenges. Unfortunately the
validation of the efficacy of IGF-1R targeted agents in large
clinical trials failed, however anecdotal single agent activity
was seen in early studies. Consequently, questions regarding
the selection of right target population and the appropriate trial
design are arising. Despite the plethora of clinical trials con-
ducted no predictive biomarker has been validated so far and
resistance mechanisms to IGF-1R inhibitors remain unclear.
The other issue to be addressed is how to best combine IGF-
1R inhibitors with other therapeutic approaches. This review
highlights the most relevant clinical data emphasizing the
main tumor types where IGF-1R inhibition showed potential
interest. We also tried to extract based on clinical and transla-
tional data some candidate biomarkers that could help better to
select patient population who potentially could benefit most
from this therapeutic approach.
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Introduction
Insulin like growth factor receptor—1 (IGF-1R) is a trans-
membrane receptor with tyrosine kinase activity found to be
over-expressed in many tumor types [1].
The crucial role of IGF-1R receptor signaling in malig-
nant transformation and in tumor cell proliferation and sur-
vival makes it a very attractive therapeutic target [2–7].
Furthermore, in preclinical models, IGF-1R signaling dem-
onstrated to interfere with numerous receptor pathways and
was implicated in the mechanism to render tumor cell resis-
tant to chemotherapy, antihormonal therapy and to anti-
EGFR and HER2 targeted therapies [8–21]. Similarly, mam-
malian target of rapamycin (m-TOR) inhibitors can activate
PI3K-Akt pathway via loss of negative feedback on IRS-1
(insulin receptor substrate—1), an effect that can be sup-
pressed by IGF-1R blockade [22–24].
Recently, the anti-neoplastic activity of IGF-1R antibod-
ies became one of the most investigated in clinical oncology.
Almost 30 candidate drugs were tested in more than 70
clinical trials conducted in a wide variety of cancers through
academia, pharmaceutical and biotechnology companies.
Early clinical data suggested the activity of IGF-1R target-
drugs in selected tumor types, such as Ewing’s sarcoma,
non-small cell lung cancer, adrenocortical carcinoma, but
the initial enthusiasm quickly encountered several challenges
and disappointment.
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In his review we focus on the most relevant clinical data
concerning tumor types where IGR-1R targeting was con-
sidered of potential interest. Meanwhile, based on existing
clinical and translational data this article describes some
potential biomarkers that could help to better identify the
patient population who would benefit most.
IGF-1R pathway
Binding of IGF-1 or IGF-2 to IGF-1R leads to receptor auto-
phosphorylation. Ligand bioavailability is elevated in some
tissues and is highly dependent on IGF-binding proteins
(IGFBP) and IGFBP-proteases. Activation of the receptor
leads to the recruitment of multiple adaptor proteins such as
insulin receptor substrates (IRS), Shc and Src homologue
and subsequent activation of at least two pro-survival sig-
naling pathways. The main event following IGF-1R phos-
phorylation is the stimulation of phophoinositol 3-kinase
(PI3K)-Akt signaling pathway, leading to cell survival.
The second pathway consists of Ras, Raf and extracellular-
signal-regulated kinase (ERK)/mitogen-activated protein
kinase (MAPK) activation, leading to tumor growth and pro-
liferation [4–6]. Figure 1
Although IGF-1R axis components can be highly altered
in cancer, little is known about molecular mechanisms in-
volved in this process. Chromosome 15q26, where IGF-1R
is located was found to be amplified in basal-like breast
cancer [25]. Low levels of IGF-1R copy number gain were
also shown in lung cancer [26, 27], pancreatic adenocarci-
noma and colon cancer [28–30]. A more recent study has
demonstrated that KIT and PDGFR-α wild type GIST have
a significantly higher level of IGF-1R amplification than
mutated ones [31]. Whereas no mutation of IGF-1R was
described to date, there are some reports of gene polymor-
phism encoding IGF-1 or IGFBP-3.
Several approaches targeting IGF-1R were developed,
including monoclonal antibodies, small molecule tyrosine
kinase inhibitors and ligand binding antibodies. The most
advanced in clinical development are monoclonal antibod-
ies. This approach is considered more selective in blocking
IGF-1R activity than tyrosine kinase inhibition. IGF-1R
shows high homology with insulin receptor (IR), thus small
molecule TKIs may block IR and receptor hybrids as well
[2]. This could be an advantage in term of metabolic con-
sequences, considering the high homology between IGF-1R
and IR. Selectivity is also important when we take into
account treatment efficacy. IR and IR/IGF-1R hybrids rep-
resent an important role in IGF signaling, and non-selective
TK inhibitors can additionally abrogate their activity. Thus
the development of techniques able to differentially assess
IGF-1R/IR hybrids and homodimers is necessary to effi-
ciently tailor anti-IGF-1R therapies.
Toxicities reported in phase I trails were uncommon and
maximal tolerated dose was not identified for either of the
drugs blocking IGF-1R investigated as single agent. Hyper-
glycemia was more frequently observed with tyrosine ki-
nase inhibitors. Up to 20% of the patients experienced this
toxicity and it was usually mild to moderate and manageable
with oral anti-diabetic medication. Other frequently regis-
tered toxicities were fatigue (8–14%), and mild skin toxic-
ities (rash, urticaria and pruritus). Hypersensitivity reaction
was a rare event [42, 44, 51, 52]. Hematological side effect
was a rare but important when occurred. Grade 3 thrombo-
cytopenia was considered a DLT with 20 mg/kg of AMG-
479 and lymphocyte count decrease occurred in 7% of the
patients treated with CP-751, 871 [44, 51].
IGF-1R inhibitors in lung cancer
Insulin growth factor receptor is overexpressed in up to 80%
of lung cancers (1). Pre-clinical data on cell lines demon-
strate that IGF-1R activation induces resistance to anti-
epidermal growth factor receptor (EGFR) therapy through
activation of PI3K-AKT pathway [12–17].
The first retrospective analysis of IGF-1R expression in
primary resected NSCLC (n0184), demonstrated a positive
correlation between IGF-1R expression and poor overall
survival [32]. The same authors recently concluded that
IGF-1R protein expression is significantly higher in squa-
mous cell carcinomas (67%) when compared with other
histologies (24%). The prognostic value of IGF-1R expres-
sion is controversial across different studies [26, 32–34]. As
an example IGF-1R gene copy number gain (3% amplifica-
tion and 24% high polysomy) had surprisingly positive
prognostic value [26]. High expression level of IGF-1R
was related to treatment response in a preclinical study on
22 NSCLC cell lines [26] and in a small cohort of patients
treated with figitumomab [26, 27, 35]. The predictive value
of IGF-1R copy number gain needs further investigation.
The initial hints of anti-IGF-1R activity in advanced
NSCLC observed across several phase I studies were sub-
sequently reproduced in one randomized phase II trial [36].
These trials investigated the efficacy of figitumomab, a
selective fully human IgG2 monoclonal antibody against
insulin like growth factor receptor 1. A total of 156 patients
were allocated to carboplatin, paclitaxel and two dose levels
of figitumumab (10 mg/Kg or 20 mg/Kg), or carboplatin
paclitaxel alone. At the moment of disease progression,
patients who received CT alone were treated with figitumu-
mab with or without other CT regimen (investigator’s dis-
cretion). The addition of figitumumab to carboplatin-
paclitaxel significantly increased the overall response rate
(54% versus 42%) [33]. Exploratory analyses revealed a
dose-dependent response in patients with squamous-cell
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histology treated with 20 mg/Kg of figitumumab plus CT
with a trend towards better PFS [33].
These encouraging results lead to its subsequent evalua-
tion in phase III trials. Two randomized phase III studies in
advanced NSCLC were prematurely discontinued after In-
dependent Data Monitoring Committees analysis indicating
that the addition of figitumumab to carboplatin-paclitaxel
would be unlikely to meet the primary endpoint of improv-
ing overall survival. Additionally more treatment related
deaths and serious adverse events were reported in the
combination arm. Cardiac toxicity was two times higher in
patients treated with figitumomab (3% versus 1.2%). High
baseline circulating IGF-1 level was predictive of better
survival in figitumomab-carboplatin-paclitaxel arm [37].
Unmet primary endpoint could be attributed at least partially
to the heterogeneous population of advanced NSCLC includ-
ed and no available stratification according to hystological
subtypes. Also, there was not an exploratory evaluation of
potential biomarkers that could be eventually related to treat-
ment response.
Finally, a third planned phase III trials evaluating the
combination of figitumumab with cisplatin and gemcitabine
(ADVIGO1017) was cancelled prior to study enrollment
[38].
Fig. 1 Downstream signaling of the IGF-1R. IGF-1R is a transmem-
brane tyrosine-kinase receptor, binding either IGF1 or IGF2. Ligand
binding leads to IRS phosphorylation and recruitment of regulatory
(p85) and catalytic (p110) subunits of PI3K and subsequently Akt
phosphorylation on threonine 308. Serine 473 of Akt is phohoshory-
lated by mTORC2 complex also activated by IGF-1R by an unknown
mechanism. Akt promotes cell survival by multiple mechanisms, inhib-
iting apoptosis and inducing expression of prosurvival genes. The
other parallel pathway, related to IGF-1R by IRS or Shc proteins is
the RAS-RAF-MAPK and JNK, resulting in cell proliferation. Nega-
tive regulation by mTORC1, S6K, JNK and ERKs induces IRS1
degradation. ( AKT—protein kinase ; ERK—extracellular-signal-reg-
ulated kinase; MAPK—mitogen activated protein kinase; Grb2—
growth factor receptor-bound protein 2; IGF-1R—insulin-like growth
factor 1 receptor; GSK3—glycogen synthase kinase 3; IRS 1—insulin-
like receptror substrate 1; MEK—mitogen-activated protein kinase;
mTOR—mammalian target of rapamycin, PI3K—phosphatidylinositol
3-kinase; PIP2—phosphatidylinositol 4,5-biphosphate; PIP3—phos-
phatidylinositol 3,4,5 triphosphate; PTEN—phosphatase and tensin
homolog; RHEB—Ras homolog enriched in brain; S6K—S6 kinase;
SOS—son of sevenless; TSC2—tuberous sclerosis complex 2)
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It’s somehow unfortunate that the initial encouraging
activity of IGF-1R targeting combined with standard che-
motherapy was not confirmed in large phase III clinical
trials. Careful selection of patient population according to
histological subtypes and smart trial design which could
lead to the identification of putative predictive biomarkers,
beyond circulating IGF-1 levels, might be more successful
and permitting less costly drug approval strategies.
IGF-1R inhibitors in sarcoma
IGF-1R axis alteration were described in many sarcoma
subtypes. In Ewing sarcoma, characterized by EWS/FLI-1
translocation, enhanced IGF-1R activity has been observed.
This was related to the transcriptional repression of the
IGFBP-3, increasing IGF-1 ligand bioavailability with
resulting IGF-1R activation. In desmoplastic small round
cell tumors (DSRCT) EWS-WT1 translocation induces a
threefold over-expression of IGF-1R [39, 40]. Gastrointes-
tinal stromal tumors (GISTs) lacking of KIT and PDGFRα
mutations presented significantly higher prevalence of IGF-
1R amplification compared to mutated ones [31]. High IGF-
1 and IGF-2 expression levels were associated to a highly
malignant phenotype and negative prognostic value in wild
type and mutant GISTs [41]. In addition, increased IGF-2
levels was described in many other sarcoma subtypes, such
as rhabdomyosarcomas, leiomyosarcomas and synovial sar-
comas, suggesting an autocrine/paracrine dependency on
this pathway [41].
Based on the strong biological rational of inhibiting IGF-
1R mediated signaling in sarcoma, many clinical trials were
conducted or are ongoing in this patient population (Table 1).
The most striking evidence of clinical activity emerges
from Ewing sarcoma. The results of two phase II trials were
recently published, evaluating the efficacy and safety of
R1507 (robatumumab, a fully human IgG1 mAb to IGF-
1R) in recurrent and refractory Ewing’s sarcomas and AMG
479 (fully human mAb to IGF-1R) in recurrent refractory
Ewing’s family of tumors and desmoplastic small round cell
tumors (DSRT). In the SARC 001 study 111 Ewing’s sar-
coma patients were treated with R1507, administered intra-
venously at 9 mg/kg weekly. Overall response rate was 9%
(1 complete response and 9 partial responses according to
RECIST criteria) and additional 21% of patients experiencing
unconfirmed partial response or disease stabilization. Thus
two patterns of response were identified, 9% of the patients
achieving a robust, durable response for about 25 weeks and 6
% having short lived responses. Median progression free
survival in this study was 5.7 months and overall survival
6.9 months [42].
Based on the encouraging phase I result with AMG 479
showing a complete response in one Ewing’s sarcoma patients
sustained after more than 3 years and a second unconfirmed
PR, a phase II trial was conducted in a population of 38
patients having a recurrent or refractory Ewing’s family of
tumors (EFT) or DSRCT. Additionally a biomarker analysis
was performed, exploring the relation between EWS translo-
cation and clinical response. Two patients (one EFT and one
DSCRT) achieved a partial response and almost half of overall
patient population had a stable disease. Clinical benefit rate
(overall response and disease stabilization for more than
24 weeks) was 17%. PFS was about 8 weeks for EFT and
19 weeks for DSCRT. Two best responses had predominantly
EWS-FLI1 type 2 transcripts, but globally no correlation
could be identified between a specific EWS translocation
and clinical benefit [43].
Twenty-nine patients with Ewing’s sarcoma and a hetero-
geneous group of other sarcoma subtypes were treated with
single agent figitumumab (CP-751, 871, Pfizer, IgG2 mono-
clonal antibody to IGF-1R) using a dose of 20 mg/kg every
3 weeks. Although primary endpoints were safety and tol-
erability, preliminary data of antitumor activity were also
provided. Twenty-two patients were evaluable for response
and half of them presented tumor shrinkage. One Ewing’s
sarcoma patients achieved a pathological complete response
and one a partial response, five additional patients having
some degree of tumor reduction but remaining in the cate-
gory of stable disease according to RECIST criteria lasting
between 4 and 16 months. Disease stabilization for 4 months
Table 1 Activity of IGF-1R targeted monoclonal antibodies (moAb) in trials including sarcoma patients





AMG 497 (51) Fully human IgG1 moAb II ESFT and DSRCT 35 2 (6%) 17(49%)
R1507-robatumumab, (48) Fully human IgG1 moAb II ESFT 111 17 (15.3%) 17(15.3%)




29 2 (EFST) 6 (ESFT)
1 (SS)
1 (FS)
ESFT Ewing’s sarcoma family of tumors, DSRCT desmoplastic small round cell tumors, SS synovial sarcoma, FS fibrosarcoma, CR complete
response, PR partial response, SD stable disease
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or longer was also noticed in one patient having a recurrent
synovial sarcoma and an additional one with fibrosarcoma
[44].
A phase II single arm study of figitumumab in Ewing’s
sarcoma is completing accrual with approximately 130 patients
[45]. A phase II trial investigating the efficacy of SCH-717454
(robatumumab, a fully human neutralizing anti IGF-1R anti-
body) has planned to include 190 patients with osteosarcoma
and Ewing’s sarcoma family of tumors [46]. A second trial
with cixutumumab (fully human IgG1moAb) is recruiting 185
patients in 5 arms with different sarcoma subtypes [47].
It can be concluded that monoclonal antibodies targeting
IGF-1R produced some activity in sarcoma patients. The
major challenge is how to select these patients and what are
the best predictive biomarkers of response to these therapies.
IGF—1R inhibitors in breast cancer
IGF-1R overexpression was observed in 44% of breast cancer
tissue specimens, showing no correlation with prognosis [48].
Circulating IGF-1 levels were associated with primary breast
cancer risk. This seems to be confined to estrogen-receptor
positive tumors and to be not significantly modified by
IGFBP-3 levels or menopausal status [49]. High IGF-1 acti-
vation was also associated with poor prognosis in breast
cancer. IGF-1 gene signature appeared to be up regulated in
basal like (ER and HER2 negative) and most of the luminal-B
tumors (ER positive but highly proliferative disease) [50].
There is extensive preclinical evidence supporting the
synergistic growth inhibition property of combined IGF-1R
and HER2 targeting treatment [18, 20, 21].
Increased IGF-1R expression was highly associated with
ER status, encoded by estrogen receptor alpha (ESR1) gene.
Reciprocal inhibition of ERS1 or IGF-1R transcript levels
was produced by siRNA knockdown of one or the other of
these targets. Furthermore it was shown in vitro and in vivo
synergism of dual targeting of these pathways by fulvestrant
or tamoxifen combined with h10H5, an IGF-1R monoclonal
antibody [29].
Increased IGF-1R signaling has been also implicated in
trastuzumab resistance. A bidirectional cross talk was detected
between the two receptors in preclinical studies. Recombinant
human IGFBP-3 showed significant inhibition of tumor growth
in trastuzumab resistant HER2 and IGF-1R overexpressing cell
lines and in vivo synergistic interaction with antiHER2 therapy
by decreasing bioavailability of IGF-1 ligand [11, 19].
A physical interaction between IGF-1R and HER2 was
found in trastuzumab resistant cells since the phosphoryla-
tion of both receptors was stimulated by IGF-1 [10]. In
another study both receptors were found in an immunopre-
citable complex [18]. HER2 heterodimerisation with other
members of HER family is a well-known phenomenon.
Besides this, heterodimers with IGF-1R were also described
in trastuzumab resistant cells. Another mechanism contribut-
ing to trastuzumab resistance is p27kip down-regulation and
this was stimulated by IGF-1 in some preclinical models [10].
Several phase I trials assessing the safety of IGF-1R
targeted agents demonstrated clinical activity in two ad-
vanced breast cancer patients receiving AVE 1642 and one
treated by AMG 479 as single agent [51, 52].
Ongoing trials in advanced breast cancer evaluate the
activity of different drug combinations with IGF-1R inhib-
itors. Based on the fact that IGF-1 is up regulated in poor
prognosis, ER positive luminal B tumors, Neo-BIG
designed a neoadjuvant trial combining letrozole with
MK-0646 (BIG 1–09). Unfortunately the clinical develop-
ment of this protocol was temporary suspended. Additional
phase II trials are evaluating the IGF-1R inhibitors associ-
ated to endocrine treatment or HER2 inhibitors in advanced
breast cancer tumors (Table 2).
Preclinical studies suggest that mTOR inhibitors are able to
up-regulate PI3K-Akt pathway by the release of the negative
feedback of S6K on IRS-1 [22, 24]. Remarkable activity was
seen in breast cancer patients in a phase I dose finding study of
oral mTOR inhibitor ridaforolimus associated to IGF-1R
monoclonal antibody, MK-0646 (dalotuzumab). Ten out of
23 patients (43%) diagnosed with metastatic breast cancer
experienced clinical activity in the expansion cohort of this
study. Most of them had hormone receptor positive tumors
with high proliferation rate, defined by Ki67 levels above 15
%. In this specific patient population the response rate was as
high as 54%. Based on these encouraging results a phase II
study is ongoing comparing exemestane with the association
of ridaforolimus and dalotozumab in HR overexpressing,
HER2 negative tumors, failing 1–2 hormonal agents and
maximum one chemotherapy regimen for metastatic disease
[58]. Surprisingly these results were not reproduced in nine
breast cancer patients included in another phase I trial com-
bining Temsirolimus with IMC-A12 (cixitumomab, fully hu-
man IgG1monoclonal antibody). Only one patient with breast
cancer had disease stabilization in this study [59]. Overall
these data are still immature and unfortunately none of these
trials was designed to evaluate in parallel molecular character-
istics of individual tumors that could predict eventually treat-
ment response or resistance.
We can conclude that the main area of interest of using
IGF-1R targeted agents in breast cancer is a combination
strategy with endocrine treatment, HER2 and mTOR targeted
agents. Clinical confirmation is in progress.
IGF-1R inhibitors in adrenocortical carcinoma (ACC)
Metastatic and non-surgically manageable adrenocortical
carcinoma (ACC) has the reputation of highly resistant
Invest New Drugs (2012) 30:2433–2442 2437
disease to classical systemic therapeutic interventions. Some
preclinical data suggests that IGF system has an important
role in ACC pathogenesis. The vast majority of human ACC
specimens display a relevant overexpression of IGF-2 tran-
scripts compared to normal adrenal tissue. This was related
to several genetic alterations such as loss of imprinting or
loss of heterozygosity of the 11p15 gene locus [60, 61].
Additionally, a high overexpression of IGF-1R was found in
ACC samples with concomitant downstream Akt activation,
demonstrating the critical role of the pathway in the patho-
genesis of this disease [61].
Preliminary antitumor activity was seen in one ACC
patient treated with OSI-906 a small-molecule IGF-1R tyrosine
kinase inhibitor in a phase I dose-escalation study. A random-
ized, double blind placebo controlled study is currently includ-
ing participants evaluating the efficacy of this drug in locally
advanced or metastatic ACC [62].
Fourteen ACC patients were treated in the phase I dose
expansion cohort with figitumumab. The results of this
study are somehow less encouraging, since no relevant
clinical activity was demonstrated. However four patients
experienced tumor shrinkage without meeting RECIST crite-
ria of partial response [63].
Conclusions and future directions
Clinical validation of IGF-1R as a target emerged with early
evidence of activity, especially in Ewing’s sarcoma and
other sarcoma subtypes, ACC and NSCLC. However evi-
dence is still limited to draw a definitive and firm conclusion
on which patient population may have benefit. Thus, despite
the overwhelming early enthusiasm, the development of
IGF-1R targeted agents arrived to an important crossroad.
Up to now there are few, if any reliable biomarkers
predicting response to IGF-1R targeting agents. Alterations
of different IGF-1R axis components were potentially related
to efficacy in preclinical studies. (Table 3) Aberrant expres-
sion of IGF-1R is detected in many cancers. Some preclinical
studies conclude that IGF-1R expression is necessary but not
sufficient to predict sensitivity. While phospho-IGF-1R levels
seem to not correlate with in vitro effectiveness of IGF-1R
targeting, total expression of IGF-1R was a better predictor of
response [27, 29]. The number of IGF-1R per cell was corre-
lated with response in some preclinical studies suggesting that
somewhere between 1300 and 10000 receptors are necessary
to obtain effective cell growth inhibition. These data should be
interpreted with caution for many reasons. IGF-1R takes part
of a complex autocrine loop involving also its ligands, IGF-1
and IGF-2, as well as intracellular adaptor proteins such as
IRS-1 and IRS-2. Meanwhile ligand bioavailability is depen-
dent on IGFBP overexpression. (Figure 2) To give an example:
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IGF-1R tyrosine kinase inhibitor) expressed high levels of
IGFBP-3 and IGFBP-6 whereas the sensitive ones showed
high expression level of IGF-1 and IGF-2 [16]. Other inves-
tigators have reported IRS-1 and IRS-2 as predictors of re-
sponse, suggesting the importance of IGF-1R axis activation in
therapeutic response as well [29]. Besides IGF-1R the ligands
may also activate IR and IGF-1R/IR hybrids. Generally tyro-
sine - kinase inhibitors are not selective for IR or IGF-1R,
while monoclonal antibodies are blocking only IGF-1R and
IGF-1R/IR hybrids. Thus the individual assessment of both
receptors and their conformation could have an impact on
response to different targeting strategies. One can also specu-
late that IGF-1R blockage by a therapeutic antibody leads to
increased ligand availability to insulin receptor thus conduct-
ing to its compensatory activation. The role of the latter in
human cancer development is frequently evoked.
No activating mutations of IGF-1R have been described
so far. On the other hand IGF-1R gene copy number gain
was identified in some tumor types, such as wild-type GIST,
breast cancer and NSCLC. This might support the idea that
IGF-1R gene amplification and its relationship to treatment
response is worthy to be evaluated.
Table 3 Potential biomarkers correlated to response to IGF-1R inhibitors in preclinical studies
Description Reference
IGF-1R expression level Intensity of IGF-1R expression was correlated to in vitro response to a humanized
monoclonal antibody in breast, colorectal and NSCLC cell lines. About 1,300 to 10,000
receptors per cell were necessary to achieve a meaningful cell growth inhibition.
[27, 29]
IGF-1R copy number gain Copy number gain of IGF-1R was identified in some tumor types such as wild-type GIST,
NSCLC and breast cancer. This was correlated to treatment response in NSCLC cell lines.
[25, 27, 31]
No activating mutation if IGF-1R was identified.
Ligands and binding proteins IGF-1 and IGF-2 gene expression level was significantly correlated to the in vitro activity
of BMS 536924 on different sarcoma cell lines, whereas IGFBP-3 and IGFBP-6
expression predicted resistance.
[16]
Receptor substrates Either insulin receptor subsrates-1 (IRS-1) and – 2 expression was predictive of response
to IGF-1R targeting agents in breast cancers. This highlights the importance of IGF-1R
axis activation in therapeutic activity.
[29]
Downstream signaling Phosphoinositide 3-kinase/Akt is a critical pathway in IGF-1R signaling. Constitutive
activation of the pathway was correlated to resistance to IGF-1R targeted agents in NSCLC.
[27]
Fig. 2 Insulin like growth factor (IGF) and insulin receptor (IR)
signaling system. The availability of IGF-1 and IGF-2 ligands is highly
influenced by IGFBPs (IGF-binding proteins), whereas insulin has
direct access to its receptor. IGF-2 can also be sequestered by IGF-
2R, which does not activate downstream signaling. Tyrosine-kinase
receptors, such as holo-IR, IGF-1R/IR hybrids and holo-IGF-1R phos-
phorylate their adaptor proteins (IRSs), by this way conducting to
downstream receptor signaling activation. Phosphoinsitide 3-kinase
(PI3K)—Akt—mammailian target of rapamycin (m-TOR) is a critical
pathway in IGF-1R signaling. ( IGF1, 2—insulin-like growth factor 1
and 2, IGFBPs—IGF binding proteins, IR—insulin receptor, IGF-1R—
insulin-like growth factor receptor-1, IGF-2R—insulin-like growth factor
receptor-2, IRS—insulin receptor substrate)
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IGF-1R phosphorylation leads to the activation of multi-
ple signaling pathways. The antiapoptotic phosphoinositol
3-kinase (PI3K) -Akt pathway is a critical pathway in IGF-1
signaling, although it can mediate also signal from other
growth factor receptors. Downstream signaling inhibition
could be not only a useful pharmacodynamic biomarker,
but also its examination before and after treatment could
be informative regarding treatment response as well.
Taking into account the above-mentioned data, clini-
cally quantifiable biomarkers should be developed, pro-
moting smarter trial design to select patient population
treated with IGF-1R targeted agents. Identification of
molecular abnormalities of IGF-1R as well as at the
level of downstream pathway components or taking IGF-
1R as a part of a complex autocrine loop would be some
examples from preclinical data worthy to be translated into
the clinics.
Another issue that might explain, at least partly the con-
cern regarding initial clinical results is that efficacy of IGF-
1R targeting as a single agent is a rare event. Thus devel-
opment of rational combinations with other anticancer
agents needs to be explored. Parallel inhibition of a second
growth factor receptor such as EGFR or HER2 or a con-
comitant downstream signaling blockade such as m-TOR or
PI3K could considerably enhance antitumor activity. Com-
bination of two HER-2 targeting antibodies directed against
different epitopes of Cerb-B2 receptor showed improvement
of clinical activity in the treatment of HER-2 amplified
metastatic breast cancer. Pertuzumab inhibits HER-2 dimer-
ization by preventing its pairing with other members of
HER receptors. Combined treatment with trastuzumab and
pertuzumab proved high efficacy in trastuzumab resistant
metastatic breast cancer as well in the neo-adjuvant setting
[64, 65]. Dual targeting of IGF-1R by two antibodies with
distinct mechanism of action producing in the mean time an
allosteric and a competitive blockage showed promising
preclinical activity in one study [66, 67].
In conclusion the clinical development of IGF-1R
targeted agents should be carefully reassessed while
placing upfront the understanding and the identification
of molecular markers predicting treatment sensitivity
and resistance and the investigation of combination thera-
peutic strategies. In addition it is of utmost importance to
optimally design clinical trials.
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